

Simone Cenci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7762880/simone-cenci-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

7,026
citations

27
h-index

47
g-index

47
ext. papers

7,909
ext. citations

7.1
avg, IF

4.81
L-index

#	Paper	IF	Citations
46	OAB-028: FAM46C-dependent tuning of endoplasmic reticulum capacity in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, S18-S19	2	
45	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021 , 138, 1554-1569	2.2	2
44	Autophagy and Protein Secretion. <i>Journal of Molecular Biology</i> , 2020 , 432, 2525-2545	6.5	32
43	The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis. <i>Cell Reports</i> , 2020 , 32, 108162	10.6	9
42	Autophagy in the regulation of protein secretion in immune cells 2020 , 141-173		
41	3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 862-864	2.4	3
40	Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation. <i>PLoS ONE</i> , 2018 , 13, e0201621	3.7	12
39	The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. <i>Blood</i> , 2017 , 129, 2132-2142	2.2	55
38	Toll-like receptor 9 stimulation can induce $\text{I}\beta$ expression and IgM secretion in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2017 , 102, 1901-1912	6.6	5
37	Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 416-429	12.9	7
36	Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis. <i>Scientific Reports</i> , 2017 , 7, 17626	4.9	6
35	Autophagy in Plasma Cells 2017 , 175-186		
34	Autophagy in Plasma Cell Ontogeny and Malignancy. <i>Journal of Clinical Immunology</i> , 2016 , 36 Suppl 1, 18-24	5.7	22
33	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
32	Assessing Heterogeneity of Osteolytic Lesions in Multiple Myeloma by ^1H HR-MAS NMR Metabolomics. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	3
31	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. <i>Cancer Cell</i> , 2016 , 29, 639-652	24.3	67
30	Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. <i>British Journal of Haematology</i> , 2015 , 168, 14-25	4.5	27

29	A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. <i>Autophagy</i> , 2015 , 11, 1161-78	10.2	67
28	Autophagy in plasma cell pathophysiology. <i>Frontiers in Immunology</i> , 2014 , 5, 103	8.4	21
27	MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 290-303	6.3	10
26	Autophagy, a new determinant of plasma cell differentiation and antibody responses. <i>Molecular Immunology</i> , 2014 , 62, 289-95	4.3	27
25	Plasma cells require autophagy for sustainable immunoglobulin production. <i>Nature Immunology</i> , 2013 , 14, 298-305	19.1	284
24	The role of autophagy in plasma cell ontogenesis. <i>Autophagy</i> , 2013 , 9, 942-4	10.2	12
23	Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. <i>PLoS ONE</i> , 2013 , 8, e74415	3.7	38
22	Iron increases the susceptibility of multiple myeloma cells to bortezomib. <i>Haematologica</i> , 2013 , 98, 971-8	6.6	27
21	Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors. <i>Journal of Leukocyte Biology</i> , 2012 , 92, 921-31	6.5	58
20	The proteasome in terminal plasma cell differentiation. <i>Seminars in Hematology</i> , 2012 , 49, 215-22	4	21
19	Proteostasis and plasma cell pathophysiology. <i>Current Opinion in Cell Biology</i> , 2011 , 23, 216-22	9	37
18	Metabolomics of B to plasma cell differentiation. <i>Journal of Proteome Research</i> , 2011 , 10, 4165-76	5.6	62
17	CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. <i>Molecular Immunology</i> , 2010 , 47, 1356-65	4.3	51
16	A new fluorogenic peptide determines proteasome activity in single cells. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 7452-60	8.3	15
15	Magnesium-enriched hydroxyapatite versus autologous bone in maxillary sinus grafting: combining histomorphometry with osteoblast gene expression profiles ex vivo. <i>Journal of Periodontology</i> , 2009 , 80, 586-93	4.6	37
14	The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. <i>Blood</i> , 2009 , 113, 3040-9	2.2	192
13	Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. <i>European Journal of Immunology</i> , 2008 , 38, 658-67	6.1	51
12	Proteotoxic stress and cell lifespan control. <i>Molecules and Cells</i> , 2008 , 26, 323-8	3.5	9

11	Managing and exploiting stress in the antibody factory. <i>FEBS Letters</i> , 2007 , 581, 3652-7	3.8	96
10	Progressively impaired proteasomal capacity during terminal plasma cell differentiation. <i>EMBO Journal</i> , 2006 , 25, 1104-13	13	120
9	Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10405-10	11.5	242
8	T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 328-37	6.3	135
7	Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. <i>Journal of Biological Chemistry</i> , 2001 , 276, 8836-40	5.4	264
6	B lymphocytes inhibit human osteoclastogenesis by secretion of TGFbeta. <i>Journal of Cellular Biochemistry</i> , 2000 , 78, 318-24	4.7	58
5	Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. <i>Blood</i> , 2000 , 96, 1873-1878	2.2	210
4	Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. <i>Journal of Clinical Investigation</i> , 2000 , 106, 1229-37	15.9	509
3	M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. <i>Journal of Clinical Investigation</i> , 2000 , 105, 1279-87	15.9	83
2	Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. <i>Blood</i> , 2000 , 96, 1873-1878	2.2	6
1	Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. <i>Journal of Clinical Investigation</i> , 1999 , 104, 503-13	15.9	196